Abstract: A metal flow device, for high pressure die casting of alloys using a method or machine having, or operable to provide, a pressurised source of molten alloy and a mould defining at least one die cavity, defines a metal flow path by which alloy received from the pressurised source is able to flow into the die cavity. A first part of the length of the flow path includes or comprises a runner, while a second part of the length of the flow path from an outlet end of the runner includes a flow-path exit module (FEM). The FEM has a form which controls the alloy flow whereby the alloy flow velocity decreases progressively from the level at the outlet end of the runner whereby, at a location at which the flow path communicates with the die cavity, the alloy flow velocity is at a level significantly below the level at the outlet end of the runner and such that, on filling of the die cavity, the alloy is able to undergo solidification in the die cavity and back along the flow path towards the runner.

Abstract: The invention relates to a method for treatment or prophylaxis of a disease or condition in an animal comprising administering to a mucosal membrane of said animal in need of such treatment a therapeutically effective amount of a drug delivery system comprising at least one physiologically active agent or prodrug thereof and at least one penetration enhancer selected from safe ester sunscreens.

Abstract: A topical cosmetic composition including: at least one water-soluble cosmetic agent; at least one oil-soluble cosmetic agent; and a dermal penetration enhancer, wherein topical application of the composition results in the delivery of the water-soluble and oil-soluble cosmetic agents into the stratum corneum as well as delivery of the oil-soluble cosmetic agent into the epidermis and dermis.

Abstract: The present invention provides a pharmaceutical composition for transdermal delivery comprising; one or more physiologically active agents; and a volatile pharmaceutically acceptable solvent; and wherein the physiological active agent forms a metastable deposit upon evaporation of the volatile solvent.

Abstract: A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents; one or more dermal penetration enhancers; and a volatile pharmaceutically acceptable carrier comprising a volatile solvent; and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum; and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (Cmax) to the average concentration (Cavg) for the physiologically active agent over the dosage interval within the range of 1 to 10.